The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016

Daniel S W Tan, Sue S. Yom, Ming S. Tsao, Harvey I. Pass, Karen Kelly, Nir Peled, Rex C. Yung, Ignacio I. Wistuba, Yasushi Yatabe, Michael Unger, Philip Mack, Murry W. Wynes, Tetsuya Mitsudomi, Walter Weder, David Yankelevitz, Roy S. Herbst, David R Gandara, David P. Carbone, Paul A. Bunn, Tony S K MokFred R. Hirsch

Research output: Contribution to journalReview article

116 Scopus citations

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.

Original languageEnglish (US)
Pages (from-to)946-963
Number of pages18
JournalJournal of Thoracic Oncology
Volume11
Issue number7
DOIs
StatePublished - 2016

Keywords

  • Brain metastases
  • EGFR mutation
  • Non-small cell lung cancer
  • Resistance
  • Therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016'. Together they form a unique fingerprint.

  • Cite this

    Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., Mack, P., Wynes, M. W., Mitsudomi, T., Weder, W., Yankelevitz, D., Herbst, R. S., Gandara, D. R., Carbone, D. P., Bunn, P. A., ... Hirsch, F. R. (2016). The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016. Journal of Thoracic Oncology, 11(7), 946-963. https://doi.org/10.1016/j.jtho.2016.05.008